novo nordisk cvs - Search News

News

Novo Nordisk, Wegovy

CVS strikes Wegovy deal with Novo Nordisk

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on Thursday.

Reuters on MSN · 1d

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

AOL · 1d

Why Novo Nordisk missed its sales estimates on weight-loss drug Wegovy: CEO

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Novo Nordisk, Guidance Hit and Copycat Drugs

Investopedia on MSN · 2d

Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.

Financial Times · 1d

Novo Nordisk cuts forecasts after replica obesity drugs hit US take-up

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions

The Wall Street Journal on MSN · 1d

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.

1don MSN

Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...

3 major takeaways from Novo Nordisk's Q1 earnings

Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations ...

Fierce Pharma7d

In major blow for Lilly, Novo strikes deal giving Wegovy preferred access on CVS Caremark formulary

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

8don MSN

CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Obesity Drug Price Wars Heat Up as CVS Picks Novo Over Lilly

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Novo Nordisk CEO on earnings, GLP-1 deal with CVS, manufacturing

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

6don MSN

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Fierce Pharma1d

Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results